We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · January 18, 2022

Very High–Risk Primary Prostate Cancer Identified by p53 Immunohistochemistry

European Urology Oncology

 

Additional Info

European Urology Oncology
p53 Immunohistochemistry to Identify Very High-risk Primary Prostate Cancer: A Prospective Cohort Study with Three Decades of Follow-up
Eur Urol Oncol 2021 Dec 27;[EPub Ahead of Print], KH Stopsack, DC Salles, JB Vaselkiv, ST Grob, LA Mucci, TL Lotan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.


Further Reading